

Usability of a Digital Registry to Promote Secondary Prevention for Peripheral Artery Disease Patients

Alisha P. Chaudhry, BA; Ronald A. Hankey, MS, MBA; Vinod C. Kaggal, BS; Huzefa Bhopalwala, MD; David A. Liedl, RN; Paul W. Wennberg, MD; Thom W. Rooke, MD; Christopher G. Scott, MS; Magali P. Disdier Moulder, PharmD, RPh; Abby K. Hendricks, PharmD, RPh; Ana I. Casanegra, MD; Robert D. McBane, 2nd, MD; Jane L. Shellum, BA, MHA; Iftikhar J. Kullo, MD; Rick A. Nishimura, MD; Rajeev Chaudhry, MBBS, MPH; and Adelaide M. Arruda-Olson, MD, PhD

Abstract

Objective: To evaluate usability of a quality improvement tool that promotes guideline-based care for patients with peripheral arterial disease (PAD).

Patients and Methods: The study was conducted from July 19, 2018, to August 21, 2019. We compared the usability of a PAD cohort knowledge solution (CKS) with standard management supported by an electronic health record (EHR). Two scenarios were developed for usability evaluation; the first for the PAD-CKS while the second evaluated standard EHR workflow. Providers were asked to provide opinions about the PAD-CKS tool and to generate a System Usability Scale (SUS) score. Metrics analyzed included time required, number of mouse clicks, and number of keystrokes.

Results: Usability evaluations were completed by 11 providers. SUS for the PAD-CKS was excellent at 89.6. Time required to complete 21 tasks in the CKS was 4 minutes compared with 12 minutes for standard EHR workflow (median, P = .002). Completion of CKS tasks required 34 clicks compared with 148 clicks for the EHR (median, P = .002). Keystrokes for CKS task completion was 8 compared with 72 for EHR (median, P = .004). Providers indicated that overall they found the tool easy to use and the PAD mortality risk score useful.

Conclusions: Usability evaluation of the PAD-CKS tool demonstrated time savings, a high SUS score, and a reduction of mouse clicks and keystrokes for task completion compared to standard workflow using the EHR. Provider feedback regarding the strengths and weaknesses also created opportunities for iterative improvement of the PAD-CKS tool.

© 2020 THE AUTHORS. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) = Mayo Clin Proc Inn Qual Out 2021;5(1):94-102

From the Department of Cardiovascular Medicine (A.P.C., H.B., D.A.L., P.W.W., T.W.R., A.I.C., R.D.M., I.J.K., R.A.N., A.M.A-O.), Information Technology (R.A.H.), Department of Health Sciences Research (V.C.K., C.G.S.), Department of Pharmacy (M.P.D.M., A.K.H.), Robert D. and Patricia E. Kem Center for the Science of

> Affiliations continued at the end of this article.

growing focus on secondary prevention for peripheral artery disease (PAD) patients has emerged after the recognition of increasing prevalence and suboptimal management.¹⁻⁵ Guideline recommended secondary prevention strategies include treatment with antiplatelet agents, statins, angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), and smoking abstention.⁶ However, many studies have shown a gap between guideline-recommended therapies and practice implementation, as most patients with PAD receive suboptimal care.^{1,5,7-10} These findings suggest need for innovative solutions to assist providers in the achievement of improved care for patients with PAD.

Recently digital disease registries have been used to identify patients with a specific condition to support research and qualityimprovement activities.¹¹⁻¹³ In a collaborative effort of informaticians, clinicians, and

Mayo Clin Proc Inn Qual Out = February 2021;5(1):94-102 = https://doi.org/10.1016/j.mayocpiqo.2020.09.012

www.mcpiqojournal.org
© 2020 THE AUTHORS. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

| Y Y Y N N Y N Y N Y N N | Y Y Y Y Y N Y Y Y Y Y Y Y | | N Y N Y N N N N Y | 1.1 1.2 1.36 0.71 1.3 0.8 0.8 0.8 1.0 1.14 | 47.9 >60 45 >80 >60 >60 >60 >60 >60 78 | ROSUVASTATIN 5 MG T ATORVASTATIN 80 MG T. ATORVASTATIN 40 MG T. ATORVASTATIN 20 MG T. |
|--|---|---|---|---|---|---|
| Y Y N Y Y N Y N Y N | Y Y N Y Y Y Y Y Y | | N Y N N N N Y | 1.36 0.71 1.3 0.8 0.8 0.8 | 45 >80 >60 >60.0 >60.0 | ATORVASTATIN 80 MG T. ATORVASTATIN 40 MG T. ATORVASTATIN 20 MG T. |
| Y N Y N Y N Y N N | Y Y Y Y Y Y Y Y Y | | N Y N N N N Y | 0.71 1.3 0.8 0.8 1.0 | >80 >60 >60.0 >60.0 | ATORVASTATIN 80 MG T. ATORVASTATIN 40 MG T. ATORVASTATIN 20 MG T. |
| N N Y N Y N Y N | Y N Y Y Y Y Y Y | | Y N N N N Y | 1.3 0.8 0.8 1.0 | >60 >60.0 >60.0 >60 | ATORVASTATIN 40 MG T. ATORVASTATIN 20 MG T. |
| N Y N Y N Y N N | N Y Y Y Y Y Y Y | | N N N N N Y | 0.8 0.8 1.0 | >60.0 >60 >60 >60 | ATORVASTATIN 40 MG T. ATORVASTATIN 20 MG T. |
| Y N Y N Y N N | Y Y Y Y Y Y Y | | N N N N Y | 0.8 | >60 >60 | ATORVASTATIN 20 MG T |
| N Y N Y N N | Y Y Y Y Y Y | | N N N Y | 1.0 | >60 | ATORVASTATIN 20 MG T |
| Y N Y N N | Y Y Y Y Y | | N N Y | 1.0 | >60 | ATORVASTATIN 20 MG T. |
| N Y N N | Y Y Y Y | | N N Y | 1.0 | >60 | |
| Y N Y N | Y Y Y Y | | N Y | 1.0 | >60 | |
| N Y N | Y Y Y | | Y | 1.0 | >60 | |
| Y N N | Y Y | | | | | |
| N | Y | | N | 1.14 | 70 | |
| N | | | | | 10 | ATORVASTATIN 80 MG T |
| 59.V | V | | N | 1.6 | 53 | |
| | | | N | | | |
| Y | Y | | N | 0.9 | 79 | ATORVASTATIN 80 MG T |
| N | N | 1 | Y | 0.5 | >60 | |
| N | Y | | N | 0.7 | >60 | SIMVASTATIN 40 MG TA. |
| N | Y | | N | | | |
| Y | Y | | N | 1.2 | >60 | ATORVASTATIN 40 MG T |
| N | Y | | N | 1.2 | >60 | |
| N | Y | | N | | | ATORVASTATIN 20 MG T |
| N | Y | | N | | | |
| N | Y | | N | 0.8 | >60 | ATORVASTATIN 80 MG T |
| Y | Y | | N | | | |
| N | Y | | N | 1.00 | >60 | ATORVASTATIN 40 MG T |
| N | Y | | N | | | |
| | N Y N N Y N | N Y Y Y N Y N Y N Y N Y N Y | N Y Y Y N Y N Y N Y N Y Y N Y N Y | N Y N Y Y N N Y N N Y N N Y N N Y N N Y N N Y N N Y N N Y N N Y N N Y N N Y N | N Y N 1.2 Y Y N 1.2 N Y N 0.8 Y Y N 0.8 Y Y N 1.00 N Y N 1.00 | N Y N I Y Y N 1.2 >60 N Y N 9 9 N Y N 9 9 N Y N 9 9 N Y N 9 9 N Y N 9 9 N Y N 9 9 |

information technologists, our institution has developed a web-based application termed *cohort knowledge solution* (CKS)¹⁴ that identifies PAD patients and summarizes clinically relevant information in a digital PAD-CKS registry. This tool aids in identifying patients with PAD by searching clinical narratives from electronic health records (EHRs) by natural language processing (NLP).^{15,16}

This study aimed to evaluate the usability of a PAD-CKS tool developed to evaluate and promote adherence to guideline-based care including treatment with antiplatelet agents, statins, ACEIs or ARBs, and smoking abstention.

METHODS

Development of the CKS Tool

Patients with PAD were identified by NLP^{15,16} used to extract PAD status from the text of narrative clinical notes in real time using a big data-empowered clinical NLP infrastructure.¹⁷ The PAD-NLP algorithm is a rule-based algorithm that uses text processing, patient classification, and assertion status.^{15,16} It has been previously shown that NLP has greater accuracy than billing code algorithms for identification of PAD from narrative clinical notes.^{15,16}

The PAD-CKS (Figure 1) displays (1) demographic information (age, sex, race,

| TABLE 1. Tasks Included in the Usabi | ility Test Scenarios for the EHR and CKS interfaces ^a |
|--------------------------------------|---|
| Group and Task | Description |
| Goal A Task I | Find patients with PAD Use the electronic health record, EPIC, or the CKS tool to find the patient information. |
| | Review pertinent narrative clinical notes in EPIC/information in the CKS to answer the question: Has PAD been diagnosed in this patient? |
| Goal B | Find status of guideline-recommended therapy for PAD. |
| Task 2 | Use the EHR/CKS to identify whether the patient is currently taking a statin drug. |
| Task 3 | Use the EHR/CKS to identify whether the patient is currently a smoker or a nonsmoker. |
| Task 4 | Use the EHR/CKS to identify whether the patient currently taking an antiplatelet agent. |
| Task 5 | Use the EHR/CKS to identify whether the patient currently taking an ACEI or an ARB. |
| Goal C | Find selected risk factors for mortality for PAD. |
| Task 6 Task 7 Task 8 | Use the EHR/CKS to identify whether CAD has been diagnosed. Use the EHR/CKS to identify whether dementia has been diagnosed. Use the EHR/CKS to identify whether type 1 or type 2 diabetes has been diagnosed. |
| Task 9 Task 10 | Use the EHR/CKS to identify whether hypertension has been diagnosed. Use the EHR/CKS to identify whether the patient has had a prior limb revascularization. |
| Task 11 | Use the EHR/CKS to identify whether renal disease has been diagnosed. |
| Goal D | Find relevant laboratory test results. |
| Task 12 Task 13 | Use the EHR/CKS to identify the most recent creatinine level. Use the EHR/CKS to identify the most recent e-GFR. |
| Task 14 | Use the EHR/CKS to identify the most recent hemoglobin ATC level. |
| Task 15 | Use the EHR/CKS to identify most recent total cholesterol levels. |
| Task 16 Task 17 | Use the EHR/CKS to identify most recent LDL levels. Use the EHR/CKS to identify most recent AST levels. |
| Task 18 | Use the EHR/CKS to identify most recent ALT levels. |
| Task 19 | Use the EHR/CKS to identify most recent fasting blood glucose. |
| Task 20 | Use the EHR/CKS to identify most recent triglyceride levels. |
| Goal E | Estimate patient risk for mortality |
| Task 21 | Use the patient information provided in the EHR/CKS to rate the patient mortality risk within the next 5 years as high, medium, or low. |

^aACEI = angiotensin-converting enzyme inhibitor; ALT = alanine aminotransferase; ARB = angiotensin-receptor blocker; AST = aspartate aminotransferase; CAD = coronary artery disease; CKS = cohort knowledge solution; e-GFR = estimated glomerular filtration rate; EHR = electronic health record; LDL = low-density lipoprotein; PAD = peripheral artery disease.

ethnicity and geocode), (2) mortality risk score estimated by automated calculator,¹⁸ (3) comorbidities used for calculation of risk score, (4) status of PAD guidelinerecommended strategies (treatment with antiplatelet agents, statins, ACEIs or ARBs, and smoking abstention), (5) selected laboratory test results (total cholesterol, low-density lipoprotein and high-density lipoprotein cholesterol), and (6) blood pressure values (systolic and diastolic). The algorithm used to design the mortality risk calculator was derived from a community-based cohort of PAD patients from Olmsted County, Minnesota, using a Cox model for 5-year all-cause mortality.¹⁸ Data elements such as demographic characteristics, status of guideline recommended strategies, laboratory test results, comorbidities (using billing codes), and blood pressure values included in the PAD-CKS tool were extracted from EHR structured data supported by a unified data platform (UDP) developed at our institution. The UDP provides technical infrastructure required for consolidation, enrichment, and access of data for the PAD-CKS tool. The study was approved by Mayo Clinic Institutional Review Board and was conducted from July 19, 2018, to August 21, 2019.

Development, Implementation, and Analysis of Usability

Two separate scenarios were developed to evaluate usability of the PAD-CKS tool and the EHR system; tasks for these scenarios were similar (Table 1). Tasks were created with 5 goals for assessment: (A) find patients with PAD, (B) find the status of guidelinerecommended therapy, (C) find selected risk factors for mortality, (D) find relevant laboratory test results, and (E) estimate patient mortality rate (Table 1).

Morae usability software was used to run usability tests and to analyze collected data.¹⁹ Each scenario was followed by user rating of ease of completion of tasks on a scale from 1 to 5, where 1 was very difficult to complete and 5 was very easy to complete. Ease of completion ratings were averaged to enable comparison of the CKS and standard EHR workflow. Providers also completed the System Usability Scale (SUS)²⁰⁻²² for the CKS. SUS is a 10-question questionnaire with 5 response options for measuring usability. The 5 response options range from "strongly agree" to "strongly disagree."20-22 Participants were asked to score the following 10 questions of the SUS questionnaire: (1) I think that I would like to use this system frequently; (2) I found the system unnecessarily complex; (3) I thought the system was easy to use; (4) I think that I would need the support of a technical person to be able to use this system; (5) I found the various functions in this system were well integrated; (6) I thought there was too much inconsistency in this system; (7) I would imagine that most people would learn to use this system very quickly; (8) I found the system very cumbersome to use; (9) I felt very confident using the system; and (10) I needed to learn a lot of things before I could get going with this system. SUS scores could range from 0 to 100. Scores greater than 70

are considered acceptable or good, whereas scores of 85 or greater indicate high level of usability or excellent score.^{21,22} Scores of 50 or less indicate poor or unacceptable usability.^{21,22} Providers were asked to provide opinions whether positive, neutral, or negative about the PAD-CKS tool. Verbal feedback was recorded by Morae software and transcribed for qualitative analysis.

An initial test run was conducted using 2 providers familiar with the PAD-CKS tool to evaluate functionalities relevant to the study questions and excluded from final analysis. Eleven providers were selected from the Division of Primary Care of the Department of Internal Medicine, or the Department of Cardiovascular Medicine including 6 licensed physicians, 2 nurse practitioners, 1 registered nurse, and 2 pharmacists to participate in 1hour test sessions. Ten providers completed both the usability tests in the EHR and CKS. One provider completed only the CKS.

Data collected from the usability test included CKS SUS scores,^{20,21} verbal feedback, ease of scenario completion, time required to complete each task, number of clicks for each task, and number of keystrokes for each task. Median values for number of clicks, time required, and number of keystrokes were used to summarize findings owing to skewed distribution of data. Means were calculated for ease of completion rating and SUS score, as data distributions of these variables had normal distribution. A nonparametric signed-rank test was used to evaluate *P* values for each category.

RESULTS

The mean SUS score of the PAD-CKS tool was 89.6, consistent with excellent system usability.²¹ Qualitative feedback by providers with suggestions for improvements are summarized in Table 2. Major comments included requests for (1) display of origin of data elements used in the CKS, (2) more information about risk score calculation, and (3) display of all information to avoid need for scrolling. Favorable qualitative feedback about the tool is summarized in Table 3. Providers indicated that overall they found the tool easy to use and the mortality risk score useful.

For the CKS, each of the 21 tasks had an average ease of completion rating greater

| TABLE 2. Transcription From Verbal Feedback: Potential Modifications for PAD-CKS Tool ^a | | | | | | |
|--|--|--|--|--|--|--|
| Summary | Provider comments | | | | | |
| Display origin of data elements in the PAD-CKS | "It would be nice to have a column specifically indicating PAD." | | | | | |
| | "Where is it capturing information from?" | | | | | |
| | "Is the patient information displayed up to date? " | | | | | |
| More information about risk mortality score calculation | "It is not clear to me if it is a mortality risk score by years or within one year." | | | | | |
| | "I am unsure of the criteria of the mortality risk score." | | | | | |
| Display all information to avoid need for scrolling | "I think it would be much better if you don't have to scroll down as much." | | | | | |
| | "It would be better if you could open the patient and have all the patient information displayed at once instead of scrolling to see the information." | | | | | |
| | "I would use it frequently if I didn't have to scroll as much." | | | | | |
| a CKS = cohort knowledge solution; PAD = peripheral artery disease. | | | | | | |

than 4, where 1 was very difficult to complete and 5 was very easy to complete. Eight of 21 tasks had an average rating of 5 for the CKS usability tests. The task with the lowest average ease of completion for the CKS was Task #2 (use EHR/CKS to identify whether the patient is currently taking a statin drug). By comparison, within the EHR none of 21 tasks had an average rating of 5 and only 6 had an average rating of 4 or greater. The task with the lowest average ease of completion in the EHR was Task #7 (use EHR/CKS to identify whether patient has been diagnosed with dementia). The greatest difference for the average ease of completion rating between the CKS and the EHR was for Task #7.

Total time required to complete 21 tasks in the CKS was 4 minutes compared with 12 minutes for the EHR (median, P = .002; Table 4). Completion of CKS tasks required 34 clicks compared with 148 clicks for the EHR (median, P = .002; Table 4). For the CKS, 8 keystrokes were required to complete task scenarios, whereas the EHR required 72 keystrokes (median, P = .004; Table 4).

Table 5 shows results for each task, and Table 6 displays accumulated results for each goal. In the CKS, Task 21 had the greatest median duration (29.6 seconds), and Task 1 had the greatest number of key strokes (n = 8) and number of mouse clicks (n = 4; Table 5). In the EHR, Task 6 had the greatest duration

| Summary | Provider comments |
|-------------------------------|--|
| Overall structure of the tool | "I like how the labs are situated together." |
| | "I like how it has the medicines together and the disease states together. I think that's helpful because you're looking at it kind of all chunked chronologically." |
| | "I like that the date the patient is put on a statin is also included." |
| Risk mortality score | "The risk mortality score is really nice to have in here." |
| Overall ease of use | "This is super user friendly and quick, I can just look at all of it by going down the row." |

Mayo Clin Proc Inn Qual Out
February 2021;5(1):94-102
https://doi.org/10.1016/j.mayocpiqo.2020.09.012
www.mcpiqojournal.org

| TABLE 4. Time, Number of Clicks, and Number of Key-strokes for Tasks Within EHR and CKS ^{a,b} | | | | | | | |
|--|------------------------------|-----------------------------|---------------------------|--|--|--|--|
| | Time required, minutes | Number of clicks | Number of keystrokes | | | | |
| EHR | 12.0 (8.4, 30.5) | 148 (67, 3503) | 72 (6, 163) | | | | |
| CKS | 4.0 (2.3, 6.7) | 34 (12, 149) | 8 (, 3) | | | | |
| EHR-CKS difference ^c | 7.9 (5.2, 27.8) ^d | 128 (36, 3354) ^e | 66 (—7, 154) ^f | | | | |

 ^{a}CKS = cohort knowledge solution; EHR = electronic health record.

^bData summarized as median (minimun, maximum) across the 21 tasks based on 11 providers who used CKS and 10 who used EHR. ^cDifference based on data from 10 providers who used both systems.

 $^{d}P = .002.$

 $^{e}P = .002.$

 ${}^{\rm f}P = .004.$

(72.2 seconds), Task 1 had the highest number of key strokes (n = 7), and Tasks 2 and 6 had the highest number of mouse clicks at (n = 10.5; Table 5). Goal B had the greatest median duration in CKS (81.1 seconds), Goal A had the greatest number of key strokes (n = 8), and Goal D had the greatest number of mouse clicks (n = 9) (Table 6). In the EHR, Goal C had the greatest median duration (n = 267.4 seconds). Goal D had the greatest number of key strokes (n = 21) and number of mouse clicks (n = 48.5; Table 6).

DISCUSSION

The major findings of this study were the high acceptance rate of the CKS tool by providers and the decreased time for providers to complete tasks relating to patient care compared with standard workflow using the EHR. These observations were demonstrated by decreased number of mouse clicks and keystrokes, greater ease in completion of tasks, a lower completion time, and high SUS scores for the CKS tool. This study also demonstrated that the CKS tool saved time for each patient encounter. Information obtained from transcribed verbal feedback from users also provides valuable information regarding which functionalities of the tool can be improved.

To our knowledge, this is the first study to evaluate usability of a digital disease registry for a research and quality improvement project. Prior studies have evaluated the usability of other health information technologies including EHRs,^{23,24} secure messaging for clinical document sharing,²⁵ and mobile health.²¹ Although other studies have described methodologies to assemble digital disease registries from EHR data for patients with psoriasis,²⁶ trophoblastic disease,²⁷ and cancer who underwent radiation therapy,¹³ the usability of these registries was not evaluated.

In the present study, an area for improvement was the request to inform providers how PAD patients were identified. Considering this feedback, we have added a "Sentence with Evidence" column to the tool displaying concepts identified by NLP as well as sentences from clinical narratives where these concepts were processed. Example of concepts and sentences extracted by NLP included: (1) lower extremity, peripheral arterial disease ("gentleman with medical comorbidities significant for diabetes mellitus type 2, atherosclerotic left lower extremity peripheral arterial disease, tobacco use, and stage 3 chronic kidney disease") and (2) leg, bypass ("male with atrial fibrillation on Coumadin, peripheral artery disease status post fem pop bypass, presented with mechanical fall"). This functionality is unique to this system because it extracts information automatically from clinical narratives by NLP. Another major comment reported by the providers was dissatisfaction with the scrolling mechanism of the tool. To address this concern, the user interface will be modified to display relevant information at the single patient view replacing the current multipatient view.¹⁴

Verbal feedback from providers also suggested that information about how the tool works should be provided before engagement with the CKS. To address this concern, a simple user instruction guide for the PAD-CKS tool will be created. This guide will address the questions "Where is it capturing information from?" and "Is the patient information

| | | CKS | | EHR | | | |
|-----------|--------------------------------|---------------------------------|----------------------------------|------------------------------|---------------------------------|-------------------------------|--|
| r Task | Median duration I (seconds) | Median number of key strokes | Median number of mouse clicks | Median duration (seconds) | Median number of key strokes | Median number of mouse clicks | |
| I | 23.5 | 8.0 | 4.0 | 31.8 | 7.0 | 3.5 | |
| 2 | 19.6 | 0.0 | 1.0 | 40.3 | 1.0 | 10.5 | |
| 3 | 13.0 | 0.0 | 1.0 | 25.8 | 0.0 | 7.5 | |
| 4 | 7.4 | 0.0 | 0.0 | 56.5 | 0.0 | 7.5 | |
| 5 | 11.7 | 0.0 | 1.0 | 17.8 | 0.0 | 2.0 | |
| 6 | 7.4 | 0.0 | 1.0 | 72.2 | 0.5 | 10.5 | |
| 7 | 4.7 | 0.0 | 0.0 | 53.5 | 2.5 | 6.5 | |
| 8 | 5.3 | 0.0 | 1.0 | 18.1 | 0.0 | 6.0 | |
| 9 | 6.7 | 0.0 | 0.0 | 9.7 | 0.0 | 1.0 | |
| 10 | 4.0 | 0.0 | 0.0 | 26.5 | 0.5 | 5.0 | |
| 11 | 8.3 | 0.0 | 1.0 | 27.7 | 0.0 | 3.0 | |
| 12 | 12.0 | 0.0 | 1.0 | 6.5 | 0.0 | 1.0 | |
| 13 | 4.4 | 0.0 | 0.0 | 5.6 | 0.0 | 0.0 | |
| 14 | 7.6 | 0.0 | 1.0 | 60.7 | 4.0 | 5.0 | |
| 15 | 8.8 | 0.0 | 1.0 | 20.1 | 3.0 | 6.0 | |
| 16 | 6.7 | 0.0 | 1.0 | 4.8 | 0.0 | 1.0 | |
| 17 | 6.9 | 0.0 | 1.0 | 35.4 | 0.0 | 5.0 | |
| 18 | 5.9 | 0.0 | 1.0 | 11.3 | 0.0 | 1.0 | |
| 19 | 4.9 | 0.0 | 0.0 | 27.4 | 0.0 | 3.5 | |
| 20 | 6.3 | 0.0 | 1.0 | 9.8 | 0.0 | 2.0 | |
| 21 | 29.6 | 0.0 | 3.0 | 45.0 | 2.0 | 3.0 | |

displayed up to date?" The instructions will state that the CKS tool extracts up-to-date patient information from EHR data daily enabled by the UDP using the big data and real-time NLP infrastructure of the EHR. We will also

add instructions regarding the risk estimator addressing the concerns "It is not clear to me if it is a mortality risk score by years or within one year" and "I am unsure of the criteria of the mortality risk score."

| TABLE 6. Accumulated Results for Each Goal ^a | | | | | | | |
|---|---|---------------------------------|----------------------------------|--------------------------------|---------------------------------|-------------------------------|--|
| | CKS | | | EHR | | | |
| Goal | Median dura- tion (seconds) | Median number of key strokes | Median number of mouse clicks | Median dura- tion (seconds) | Median number of key strokes | Median number of mouse clicks | |
| А | 23.5 | 8.0 | 4.0 | 31.8 | 7.0 | 3.5 | |
| В | 81.1 | 0.0 | 6.0 | 173.7 | 2.0 | 42.5 | |
| С | 35.9 | 0.0 | 4.0 | 267.4 | 7.5 | 41.0 | |
| D | 68.0 | 0.0 | 9.0 | 244.2 | 21.0 | 48.5 | |
| Е | 29.6 | 0.0 | 3.0 | 45.0 | 2.0 | 3.0 | |
| ^a CKS | a CKS = cohort knowledge system; EHR = electronic health record. | | | | | | |

Mayo Clin Proc Inn Qual Out = February 2021;5(1):94-102 = https://doi.org/10.1016/j.mayocpiqo.2020.09.012 www.mcpiqojournal.org

The CKS tool can transform clinical practice by bringing the right information to the right provider efficiently enabling practice standardization. The CKS tool is also generalizable to other diseases. However, diseasespecific algorithms to populate the tool automatically should be developed and evaluated before implementation and dissemination.

CONCLUSION

Usability evaluation of the PAD-CKS tool demonstrated time-savings, a high SUS score, and a reduction of mouse clicks and keystrokes for task completion compared to standard workflow using the EHR. Provider feedback regarding the strengths and weaknesses also created opportunities for iterative improvement of the PAD-CKS tool.

We will use these research observations to develop a more user-friendly PAD-CKS tool. The PAD-CKS will expedite the translation of guideline-recommended strategies into realworld practice settings by displaying individualized information summarizing use of guideline recommended strategies by each patient which will support point-of-care discussion to promote adherence to these strategies.

ACKNOWLEDGMENTS

Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of National Institutes of Health (K01HL124045). The content is solely the responsibility of the authors, and it does not necessarily represent the official views of the National Institutes of Health. The authors thank Tessa L. Files, Rebecca M. Olson, and Katie M. Nagel for secretarial support.

Abbreviations and Acronyms: ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CKS = cohort knowledge solution; EHR = electronic health record; NLP = natural language processing; PAD = peripheral artery disease; SUS = Systems Usability Score; UDP = unified data platform

Affiliations (Continued from the first page of this article.): Health Care Delivery (J.L.S., R.A.N., R.C.), and Department of Internal Medicine (R.C.); Mayo Clinic and Mayo Foundation, Rochester, MN

Grant Support: Study supported by National Heart, Lung and Blood Institute of National Institutes of Health (K01HL124045). The content is solely responsibility of the authors and does not necessarily represent official views of National Institutes of Health.

Potential Competing Interests: The authors report no competing interests.

Correspondence: Adelaide M. Arruda-Olson, MD, PhD, 200 First Street SW, Rochester, MN 55905 (ArrudaOlson. Adelaide@mayo.edu).

ORCID

Christopher G. Scott: https://orcid.org/0000-0003-1340-0647; Magali P. Disdier Moulder: https://orcid.org/0000-0002-8557-4112; Abby K. Hendricks: https://orcid.org/ 0000-0001-8740-0899; Ana I. Casanegra: https://orcid. d.org/0000-0001-6114-4284; Robert D. McBane: https:// orcid.org/0000-0001-8727-8029; Iftikhar J. Kullo: https:// orcid.org/0000-0001-8524-3471; Adelaide M. Arruda-Olson: https://orcid.org/0000-0001-9541-9899

REFERENCES

- Berger JS, Ladapo JA. Underuse of prevention and lifestyle counseling in patients with peripheral artery disease. J Am Coll Cardiol. 2017;69(18):2293-2300.
- Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317-1324.
- Kalbaugh CA, Kucharska-Newton A, Wruck L, et al. Peripheral artery disease prevalence and incidence estimated from both outpatient and inpatient settings among Medicare fee-forservice beneficiaries in the Atherosclerosis Risk in Communities (ARIC) Study. J Am Heart Assoc. 2017;6(5):e003796.
- McDermott MM. The magnitude of the problem of peripheral arterial disease: Epidemiology and clinical significance. Cleve Clin J Med. 2006;73(Suppl 4):S2-S7.
- Arruda-Olson AM, Moussa Pacha H, Afzal N, et al. Burden of hospitalization in clinically diagnosed peripheral artery disease: A community-based study. Vasc Med. 2018;23(1):23-31.
- 6. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;69(11):1465-1508.
- Moussa Pacha H, Mallipeddi VP, Afzal N, et al. Association of ankle-brachial indices with limb revascularization or amputation in patients with peripheral artery disease. JAMA Netw Open. 2018;1(8):e185547.
- Chaudhry AP, Afzal N, Abidian MM, et al. Innovative informatics approaches for peripheral artery disease: Current state and provider survey of strategies for improving guideline-based care. *Mayo Clin Proc Innov Qual Outcomes.* 2018;2(2):129-136.
- Armstrong EJ, Chen DC, Westin GG, et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc. 2014;3(2):e000697.
- Hussain MA, Al-Omran M, Lindsay TF. Risk-reduction program for cardiovascular and limb events in patients with peripheral arterial disease—Reply. JAMA Surg. 2016;151(10):990-991.
- Demiris G, Kneale L. Informatics systems and tools to facilitate patient-centered care coordination. Yearb Med Inform. 2015; 10(1):15-21.

- **12.** Liaw ST, Taggart J, Yu H, Rahimi A. Electronic health records and disease registries to support integrated care in a health neighbourhood: An ontology-based methodology. AMIA Jt Summits Transl Sci Proc. 2014;2014:50-54.
- Chen AM, Kupelian PA, Wang PC, Steinberg ML. Development of a radiation oncology-specific prospective data registry for research and quality improvement: A clinical workflow-based solution. JCO Clin Cancer Inform. 2018;2:1-9.
- 14. Sundaram DSB, Arunachalam SP, Berg TM, et al. Improving workload management for reducing readmissions and follow-up visits in outpatient practice using a novel application–Cohort Knowledge Solutions (CKS). Lincoln, NE: 2017 IEEE International Conference on Electro Information Technology (EIT); 2017.
- Afzal N, Sohn S, Abram S, et al. Mining peripheral arterial disease cases from narrative clinical notes using natural language processing. J Vasc Surg. 2017;65(6):1753-1761.
- Afzal N, Sohn S, Abram S, Liu H, Kullo JJ, Arruda-Olson AM. Identifying peripheral arterial disease cases using natural language processing of clinical notes. *IEEE EMBS Int Conf Biomed Health Inform.* 2016;2016:126-131.
- Kaggal VC, Elayavilli RK, Mehrabi S, et al. Toward a learning health-care system - Knowledge delivery at the point of care empowered by big data and NLP. *Biomed Inform Insights*. 2016;8(Suppl 1):13-22.
- Arruda-Olson AM, Afzal N, Priya Mallipeddi V, et al. Leveraging the electronic health record to create an automated real-time prognostic tool for peripheral arterial disease. J Am Heart Assoc. 2018;7(23):e009680.
- 19. Morae TW. Usability Testing Software. Available at: https:// www.techsmith.com/morae.html. Accessed October 7, 2019.

- Brooke J. SUS: A "quick and dirty" usability scale, Usability Evaluation in Industry. London: McClelland IL, Taylor & Francis group; 1996:189-194.
- Georgsson M, Staggers N. Quantifying usability: An evaluation of a diabetes mHealth system on effectiveness, efficiency, and satisfaction metrics with associated user characteristics. J Am Med Inform Assoc. 2016;23(1):5-11.
- Bangor AKP, Miller J. Determining what individual SUS scores mean: Adding an adjective rating scale. J Usability Stud. 2009; 4(3):114-123.
- Mazur LM, Mosaly PR, Moore C, Marks L. Association of the usability of electronic health records with cognitive workload and performance levels among physicians. JAMA Netw Open. 2019;2(4):e191709.
- Ratwani RM, Fairbanks RJ, Hettinger AZ, Benda NC. Electronic health record usability: Analysis of the user-centered design processes of eleven electronic health record vendors. J Am Med Inform Assoc. 2015;22(6):1179-1182.
- 25. Jahn MA, Porter BW, Patel H, Zillich AJ, Simon SR, Russ AL. Usability assessment of secure messaging for clinical document sharing between health care providers and patients. *Appl Clin Inform.* 2018;9(2):467-477.
- Schneeweiss M, Merola JF, Karlson EW, Solomon DH. Rationale and design of the Brigham cohort for psoriasis and psoriatic arthritis registry (COPPAR). BMC Dermatol. 2017; 17(1):11.
- Sauthier P, Breguet M, Rozenholc A, Sauthier M. Quebec trophoblastic disease registry: How to make an easy-touse dynamic database. Int J Gynecol Cancer. 2015;25(4): 729-733.